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inhibited the phosphorylation of p38 and JNK kinases along with its
enhancing effect on MKP-1 expression; and when MKP-1 was down-
regulated by siRNA, aurothiomalate’s ability to inhibit p38 and JNK
phosphorylation, and COX-2 expression reduced signiﬁcantly.
Conclusions: The results provide a novel mechanism for the anti-
inﬂammatory action of aurothiomalate through increased MKP-1 expres-
sion and reduced p38 and JNK MAP-kinase activation, and COX-2
expression. The results propose MKP-1 as a promising novel target for
the development of disease modifying drugs for RA and OA.
*Murine H4 chondrocyte cell line was kindly provided by Peter van der
Kraan, Laboratory of Experimental Rheumatology, University Medical
Center Nijmegen, Netherlands.
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Purpose: Aggrecan, the main proteoglycan of articular cartilage, is
composed of a core protein containing 3 globular domains G1, G2 and
G3. The interglobular domain between G1 and G2 is the primary site for
enzyme attacks of the molecule, matrix metalloproteinases (MMPs) and
aggrecanases, generating fragments with speciﬁc N-terminal ends. The
aim of this study was to identify aggrecan fragments circulating in hu-
man serum/plasma with speciﬁc antibodies corresponding to neoepitope
generated by aggrecanases.
Methods: Pools of serum from controls (n = 22; mean age: 62 yrs ±2.7)
and patients suffering from osteoarthritis (n = 19; mean age: 64±4) and
plasma from patients suffering from RA (n= 20; 10 men and 10 women,
mean age: 61.7 yrs ±3.9, DAS> 4.8) were investigated with afﬁnity
puriﬁcation and Western blots using two monoclonal antibodies. First,
monoclonal antibody BC-3 recognizing a neoepitope generated by aggre-
canases in position 374-ARGSV. Secondly, a monoclonal antibody F-78
was used recognizing a repetitive epitope exposed at least twice on G1
and G2 domains.
Results: In Western blot, BC-3 recognized a band migrating at 45 kDa in
RA patients only. The strong reactivity was abolished by pre-incubation
with the peptide corresponding to BC-3 epitope. To further investigate the
distribution of ARGSV-carrying neoepitopes in RA plasma, we subjected
the plasma to afﬁnity puriﬁcation using either BC-3 or F-78. Again, the
major reactivity was conﬁned to a 45 kDa band using either BC-3 or F-78
as detecting antibody in western blots of the eluted material.
Conclusions: We have identiﬁed an aggrecan fragment of MW 45 kDa
generated by aggrecanase cleavage with a N-terminal neoepitope 374-
ARGSV and containing G2 domain suggesting that this fragment is a
good candidate marker for a sandwich assay using monoclonal antibodies
BC-3 and F-78. Apparently, this fragment of aggrecan is primarily found
in circulation of RA patients and additional investigations are underway
to determine the molecular nature of this fragment.
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Purpose: One hallmark of the progression of osteoarthritis and rheuma-
toid arthritis is the gradual destruction of articular cartilage in affected
joints, in part mediated the matrix metalloproteases (MMPs) and aggre-
canases. Collagen type II is found almost exclusively in cartilage tissue
where it constitutes over 60% of the dry weight. Degradation of collagen
type II is for the major part mediated by MMPs. Because of the abundance
of collagen type II in cartilage and its tissue speciﬁcity, MMP generated
fragments of type II collagen (neo-epitopes) are highly interesting as
cartilage degradation markers. The aim of this study was to develop
new biochemical enzyme immuno assays (EIA) of MMP cleaved collagen
type II fragments to be used as markers of cartilage degradation.
Methods: Two neoepitopic sites representing ubiquitous MMP-generated
fragments of collagen type II identiﬁed from cleavage of collagen type II
were selected. The two neoepitopes corresponded to cleavage between
amino acids 845–846 (neoepitope I) and 872–873 (neoepitope II).
Peptides reﬂecting the neoepitopic sites (846LTGPAG and RDGAAG872)
were synthesized and used for immunization of balb/C mice and rabbits.
Competitive EIA assays were established using biotinylated synthetic
peptide as coater and the immune sera as primary antibody. The assays
were used to proﬁle the proteolytic events in the well characterized ex vivo
articular cartilage explant model. The cartilage explants included catabol-
ically stimulated TNFa (tumor necrosis factor alpha) and oncostatin M
cultures, non-stimulated cultures, and metabolically inactive cultures.
Results: In catabolically stimulated bovine cartilage explant cultures a
low concentration of neoepitope I of below 50ng/ml was found in samples
collected day 3, 6, and day 11. However after prolonged catabolic stim-
ulation of 22 days a more than 20-fold dramatic increase was observed
reaching a level higher than 1000 ng/ml. In comparison the control culture
of non-stimulated explant culture media had the same low level below
50ng/ml on day 3, 6, and 11, and reached only 100 ng/ml at day 22.
The metabolically inactive culture remained below 50ng/ml during the
complete culture period. A similar pattern of a dramatic increase in the
22-day catabolically stimulated culture was observed in human articular
cartilage explant cultures. The pattern of other marker of neopitope II
mirrored that of neoepitope I.
Conclusions: Two new immunoassays of neoepitope markers of collagen
type II degradation were established. Measurement of these neoepitopes
in both the bovine and human ex vivo articular cartilage explant model
demonstrated that the two markers reﬂect late cartilage degradation.
Further studies are needed to investigate whether these fragments are
of clinical relevance.
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Purpose: The objective of the present study was to investigate the
changes of serum level of cartilage oligomeric matrix protein (COMP)
during a 30-min exercise after 12-weeks of regular impact or non-impact
exercise.
Methods: Blood samples were drawn from 33 healthy sedanter males
immediately before and after and 0.5 h after a 30-min walking exercise
on a motor-driven treadmill at 5 km/h speed. Serum COMP concentra-
tions were determined using a commercial enzyme-linked immunosorbent
assay (AnaMar Medical, Go¨teborg, Sweden). After ﬁrst measurements
participants were randomly and equally assigned to impact group (run-
ning, n = 11) non-impact group (swimming, n = 11), and control conditions
(n = 11). All exercise groups participated in sessions of 40 minutes per
day, 3 days per week for 12 weeks. Each session started with a 5min.
of warm-up, continuing with main set for 30min. at their individual target
heart rate zone which was determined according to the ACSMs’ guide-
lines (60−70% of heart rate reserve) and lasted with a 5min. cool down
period. The target heart rate reserve (HRR) was determined by Karvo-
nen formula (Bompa, 1994). Participants in running and cycling groups
partake sessions in the human performance laboratory one by one, three
times a week throughout their weekly Schedule (throughout Mondays,
Wednesdays and Fridays) which was determined by the instructor while
swimming group perform exercise sessions in indoor swimming pool. The
heart rate of the subjects was monitored with Heart rate monitors (Polar
Vantage NV Heart Rate Monitor) during exercise sessions. Throughout
the 12-week period, the control group was told not to participate in any
organized or structured exercise and continue their daily life activities.
At the end of the 12-weeks intervention period, post tests were applied
with the same procedure of pre-tests. The experimental protocol was
approved by local ethics committee. All subjects signed a consent form
after being fully informed of the study’s methods, possible side effects and
the purpose. Serum COMP concentrations within the groups of running,
swimming and control were compared using separate repeated measures
of analysis of variance (repeated-ANOVA). Main effect was compared
for multiple comparisons by Bonferroni conﬁdence interval adjustment.
Statistical computation was performed using the SPSS. The level of
statistical signiﬁcance was accepted as p< 0.05.
Results: In the pre-tests measurements, signiﬁcant change between the
serum COMP concentrations were found only at P< 0.1 level. Immediately
after the walking exercise, serum COMP concentrations were increased
signiﬁcantly in running (P=0.084) and control groups (P=0.064). In the
